INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

NEW YORK , Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Beam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On September 8, 2026, Beam issued a press release "announc[ing] updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD)." Although the Company said that "treatment with single-dose BEAM-302 was well tolerated with an acceptable safety profile in both Part A and Part B cohorts", the press release also disclosed that "[t]ransient and predominantly Grade 1 alanine transaminase (ALT) and/or aspartate aminotransferase (AST) elevations were also observed." On this news, Beam's stock price fell $2.83 per share, or 9.54%, to close at $26.83 per share on September 8, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP 21 % more press release views with Request a Demo × Modal title